BIO Conference to feature two U.S. representatives.
Share:
Press Release Summary:
BIO announces discussion, Producing "21st Century Cures"—2015 U.S. Legislative Outlook, with U.S. Rep. Fred Upton (R - MI), Chairman of the Committee on Energy and Commerce, and U.S. Rep. Diana DeGette (D - CO), Chief Deputy Whip, to take place on February 9, at the 17th annual BIO CEO & Investor Conference. Conference program will also feature one-on-one conversations with leading biopharmaceutical executives and analysts, followed by interactive question and answer session.
Original Press Release:
17th Annual BIO CEO and Investor Conference to Feature U.S. Representatives Fred Upton and Diana DeGette
Reps. Upton and DeGette will discuss 21st Century Cures Initiative to help expedite cures and treatments
BIO CEO & Investor Conference 2015
WASHINGTON -- The Biotechnology Industry Organization (BIO) announces today a discussion, Producing "21st Century Cures"—2015 U.S. Legislative Outlook, with U.S. Rep. Fred Upton (R - MI), Chairman of the Committee on Energy and Commerce, and U.S. Rep. Diana DeGette (D - CO), Chief Deputy Whip, to take place on February 9, noon to 1 p.m. at the 17th annual BIO CEO & Investor Conference. The event, to be held in New York City, February 9-10, 2015, is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
“The biotech industry is eager to answer the call for 21st Century Cures, led by Chairman Upton and Representative DeGette, to revolutionize the drug development process and ensure that patients fully realize the benefits of advancements in biotechnology”
“The biotech industry is eager to answer the call for 21st Century Cures, led by Chairman Upton and Representative DeGette, to revolutionize the drug development process and ensure that patients fully realize the benefits of advancements in biotechnology,” said BIO President & CEO Jim Greenwood. “This goal can only be realized in an environment of forward-looking public policies that sustain scientific discovery and promote biomedical research and investment. I am pleased to sit down with Chairman Upton and Representative DeGette to discuss new approaches for expediting the discovery, development and delivery of breakthrough treatments and cures.”
The conference program will also feature candid, one-on-one conversations with leading biopharmaceutical executives and analysts, followed by an interactive question and answer session. The complete list of Fireside Chat participants includes:
Ian C. Read, Chairman of the Board and CEO, Pfizer
Ron Cohen, M.D., President & CEO, Acorda Therapeutics
Peter Greenleaf, CEO, Sucampo Pharmaceuticals, Inc.
John Maraganore, Ph.D., CEO, Alnylam Pharmaceuticals
John F. Milligan, Ph.D., President and COO, Gilead Sciences
To learn more about the BIO CEO & Investor Conference, including registration, programming and partnering information, please visit here.
The event also provides the opportunity to arrange meetings between investors, companies and industry business development, licensing and therapeutic franchise heads. One-on-one meetings will be powered by BIO One-on-One Partnering™, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. This industry-specific, web-based interactive software enables participants to move efficiently from the identification of prospective partners to discussion and negotiations.
Complimentary investor registration is available for those who qualify. For information regarding qualified investor criteria and to apply for investor registration, please visit here.
Media registration is complimentary for credentialed members of the media. All registrations are subject to verification of credentials.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors including Double Helix Sponsor Merck, Helix Sponsors Eli Lilly and Pfizer, and Supporting Bank Sponsors BMO Capital Markets, HC Wainwright & Co., JMP Securities, Lazard and ROTH Capital Partners, LLC.
About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.
Upcoming BIO Events
BIO CEO & Investor Conference
February 9-10, 2015
New York City, NY
BIO-Europe Spring
March 9-11, 2015
Paris, France
BIO Asia International Conference
March 24-25, 2015
Tokyo, Japan
BioEquity Europe
May 19-20, 2015
Vienna, Austria
BIO International Convention
June 15-18, 2015
Philadelphia, PA
Contacts
Biotechnology Industry Organization (BIO)
Abigail Hirsch, 202-962-9235
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
